Relmada Therapeutics to Present New Preclinical Data on its Psilocybin Program at AASLD The Liver Meeting® 2023PRNewsWire • 10/11/23
Relmada Therapeutics to Participate in the Jefferies Inaugural Biotech CNS/Neuro SummitPRNewsWire • 10/09/23
Relmada Therapeutics to Present Data from its REL-1017 and Psilocybin Programs at the 36th European College of Neuropsychopharmacology (ECNP) CongressPRNewsWire • 10/06/23
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 09/27/23
Relmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1017 in Major Depressive DisorderPRNewsWire • 09/20/23
Relmada Therapeutics: Run Up Likely Into Phase 3 Results, Enhanced By Possible Interim ReadoutSeeking Alpha • 09/01/23
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 08/25/23
Relmada Therapeutics Announces Dosing of First Patient in Relight, a Phase 3 Trial of REL-1017 for the Adjunctive Treatment of Major Depressive DisorderPRNewsWire • 08/23/23
Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial ResultsPRNewsWire • 08/08/23
Relmada Therapeutics to Report Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 8, 2023PRNewsWire • 08/01/23
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses In Excess of $250,000 to Contact the FirmAccesswire • 07/25/23
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the FirmAccesswire • 07/06/23
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the FirmAccesswire • 07/03/23
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 06/17/23
RLMD NOTICE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Relmada Therapeutics, Inc. Investors With Losses to Inquire About Securities Class Action Investigation - RLMDPRNewsWire • 06/14/23
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 06/12/23
Relmada Therapeutics to Participate in the Goldman Sachs Global Healthcare ConferencePRNewsWire • 06/08/23
ROSEN, A LEADING LAW FIRM, Encourages Relmada Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - RLMDPRNewsWire • 06/03/23
Relmada Therapeutics to Participate in the 2023 Jefferies Global Healthcare ConferencePRNewsWire • 06/02/23
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 05/31/23
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Relmada Therapeutics, Inc. - RLMDPRNewsWire • 05/30/23
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the FirmAccesswire • 05/26/23
INVESTIGATION ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 05/25/23
